174 related articles for article (PubMed ID: 34603326)
21. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[TBL] [Abstract][Full Text] [Related]
22. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study.
Ramírez E; Romero-Garrido JA; López-Granados E; Borobia AM; Pérez T; Medrano N; Rueda C; Tong HY; Herrero A; Frías J
Thromb Res; 2014 Jun; 133(6):1045-51. PubMed ID: 24731561
[TBL] [Abstract][Full Text] [Related]
23. Intravenous Immunoglobulin as a Treatment for Intractable Epilepsy Secondary to Focal Cortical Dysplasia: A Meta-analysis.
Al Amrani F; Dudley R; Bello-Espinosa LE; Rosenblatt B; Srour M; Sébire G
Pediatr Neurol; 2017 Nov; 76():79-81. PubMed ID: 28969879
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.
Singh-Grewal D; Kemp A; Wong M
Arch Dis Child; 2006 Aug; 91(8):651-4. PubMed ID: 16638785
[TBL] [Abstract][Full Text] [Related]
25. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
[TBL] [Abstract][Full Text] [Related]
26. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
27. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.
Kaba S; Keskindemirci G; Aydogmus C; Siraneci R; Erol Cipe F
Eur Ann Allergy Clin Immunol; 2017 Jan; 49(1):11-14. PubMed ID: 28120600
[TBL] [Abstract][Full Text] [Related]
28. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases.
Sherer Y; Levy Y; Langevitz P; Rauova L; Fabrizzi F; Shoenfeld Y
Pharmacology; 2001; 62(3):133-7. PubMed ID: 11287813
[TBL] [Abstract][Full Text] [Related]
29. Maculopapular rash in the convalescent phase of Kawasaki disease: case series and literature review.
Takeuchi M; Oda Y; Suzuki I
Eur J Pediatr; 2013 Mar; 172(3):405-7. PubMed ID: 23192460
[TBL] [Abstract][Full Text] [Related]
30. Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: a real clinical threat?
Mignogna MD; Fortuna G; Ruoppo E; Adamo D; Leuci S; Fedele S
Am J Clin Dermatol; 2007; 8(5):291-9. PubMed ID: 17902731
[TBL] [Abstract][Full Text] [Related]
31. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
32. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
Tcheurekdjian H; Martin J; Kobayashi R; Wasserman R; Hostoffer R
Allergy Asthma Proc; 2006; 27(6):532-6. PubMed ID: 17176791
[TBL] [Abstract][Full Text] [Related]
33. Intravenous Immunoglobulin Therapy in Refractory Autoimmune Dysautonomias: A Retrospective Analysis of 38 Patients.
Schofield JR; Chemali KR
Am J Ther; 2019; 26(5):570-582. PubMed ID: 29781817
[TBL] [Abstract][Full Text] [Related]
34. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
35. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
[TBL] [Abstract][Full Text] [Related]
36. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
37. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions.
Watad A; Amital H; Shoenfeld Y
Lupus; 2017 Sep; 26(10):1015-1022. PubMed ID: 28420062
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 May; 41(5):812-23. PubMed ID: 17440006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]